Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study

Author:

Arnold Heather M1,Hollands James M2,Skrupky Lee P3,Smith Jennifer R4,Juang Paul H5,Hampton Nicholas B6,McCormick Sandra7,Reichley Richard M8,Hoban Alex9,Hoffmann Justin10,Micek Scott T11,Kollef Marin H12

Affiliation:

1. Heather M Arnold PharmD, Clinical Pharmacist, Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO

2. James M Hollands PharmD, Clinical Pharmacist, Department of Pharmacy, Barnes-Jewish Hospital

3. Lee P Skrupky PharmD, Clinical Pharmacist, Department of Pharmacy, Barnes-Jewish Hospital

4. Jennifer R Smith PharmD, Clinical Pharmacist, Department of Pharmacy, Barnes-Jewish Hospital

5. Paul H Juang PharmD, Assistant Professor, Pharmacy Practice, St. Louis College of Pharmacy

6. Nicholas B Hampton PharmD, Clinical Decision Support Pharmacist, Center for Clinical Excellence, Barnes-Jewish Hospital

7. Sandra McCormick MSCIS, Senior Analyst, Center for Clinical Excellence, Barnes-Jewish Hospital

8. Richard M Reichley RPh, Manager, Pharmacist, Center for Clinical Excellence, Barnes-Jewish Hospital

9. Alex Hoban BS, Student, MD program, Division of Pulmonary and Critical Care Medicine, School of Medicine, Washington University, St. Louis

10. Justin Hoffmann, Student, PharmD program, St. Louis College of Pharmacy

11. Scott T Micek PharmD, Clinical Pharmacist, Department of Pharmacy, Barnes-Jewish Hospital

12. Marin H Kollef MD, Division of Pulmonary and Critical Care Medicine, School of Medicine, Washington University

Abstract

BACKGROUND: β-Lactam antibiotics demonstrate time-dependent killing. Prolonged infusion of these agents is commonly performed to optimize the time the unbound concentration of an antibiotic remains greater than the minimum inhibitory concentration and decrease costs, despite limited evidence suggesting improved clinical results. OBJECTIVE: To determine whether prolonged infusion of β-lactam antibiotics improves outcomes in critically ill patients with suspected gram-negative infection. METHODS: We conducted a single-center, before-after, comparative effectiveness trial between January 2010 and January 2011 in the intensive care units at Barnes-Jewish Hospital, an urban teaching hospital affiliated with the Washington University School of Medicine in St. Louis, MO. Outcomes were compared between patients who received standardized dosing of meropenem, piperacillin-tazobactam, or cefepime as an intermittent infusion over 30 minutes (January 1, 2010, to June 30, 2010) and patients who received prolonged infusion over 3 hours (August 1, 2010, to January 31, 2011). RESULTS: A total of 503 patients (intermittent infusion, n = 242; prolonged infusion, n = 261) treated for gram-negative infection were included in the clinically evaluable population. Approximately 50% of patients in each group received cefepime and 20% received piperacillin-tazobactam. More patients in the intermittent infusion group received meropenem (35.5% vs 24.5%; p = 0.007). Baseline characteristics were similar between groups, with the exception of a greater occurrence of chronic obstructive pulmonary disease (COPD) in the intermittent infusion group. Treatment success rates in the clinically evaluable group were 56.6% for intermittent infusion and 51.0% for prolonged infusion (p = 0.204), and in the microbiologically evaluable population, 55.2% for intermittent infusion and 49.5% for prolonged infusion (p = 0.486). Fourteen-day, 30-day, and inhospital mortality rates in the clinically evaluable population for the intermittent and prolonged infusion groups were 13.2% versus 18.0% (p = 0.141), 23.6% versus 25.7% (p = 0.582), and 19.4% versus 23.0% (p = 0.329). CONCLUSIONS: Routine use of prolonged infusion of time-dependent antibiotics for the empiric treatment of gram-negative bacterial infections offers no advantage over intermittent infusion antibiotic therapy with regard to treatment success, mortality, or hospital length of stay. These results were confirmed after controlling for potential confounders in a multivariate analysis.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3